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with history of stroke were excluded and total 2,119 patients were analyzed. Ischemia
was detected by brain MRA in 253 patients (group A), but not in 1866 patients (group
B). Preoperative characteristics, follow-up survival, and cardiac and neurological
events were investigated.
Results: The median follow-up period was 2.2 years. Univariate analysis showed that
patients in group A (65.4 ± 8.3 years) were older than those in group B (63.0 ± 9.0
years) (p<0.001). Diabetes mellitus was more common in group A (48.6%) than group
B (40.9%) (p=0.019). The prevalence of chronic kidney disease was higher in group
A (63 patients: 24.9%) compared with group B (324 patients: 17.4%) (p=0.004). The
prevalence of peripheral vascular disease was higher in group A (13 patients: 5.1%)
than in group B (39 patients: 2.1%) (p = 0.003). Euroscore was higher in group A (4.3
±2.3) than group B (3.6 ±2.2) (p<0.001). Survival rate was significantly lower (93.4%
vs. 90.1%, p = 0.008), and freedom from stroke or major adverse cardiac and
cerebrovascular event were significantly lower in group A (98.0% vs. 96.0%, p = 0.015,
and 91.9% vs. 88.2%, p = 0.001).
Conclusion: Preexisting ischemic findings on brain MRA in patients who undergoing
CABG were related to death, stroke, and major adverse cardiac and cerebrovascular
event.
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Background: Endovascular abdominal aortic aneurysm (AAA) has evolved since first
being approved in the US in 1999. Outcomes have changed with increased operator
experience and the approval of new devices. The Endurant stent graft system
(Medtronic, Santa Rosa CA) which was approved in late 2010 is the first next
generation device to be commercialized in the US. This device seeks to expand the
indications of EVAR in short, angulated necks, as well as, patients with small peripheral
access vessels. However, are US pivotal study results indicative of global experience?
Methods: Over 1400 patients have been enrolled in Endurant clinical studies or
registries since first in human studies commenced in Europe. The three studies used in
this analysis are the Endurant European study which enrolled 80 patients, the US
Pivotal study which enrolled 150 patients, and the ENGAGE global registry. Data from
the ENGAGE registry includes results from the first 839 patients at 30 days and the
first 152 patients at 1 year.
Results: Deployment success was achieved in 99.6% of patients across all studies. In
the US Pivotal study there was 0% all-cause mortality at 30 days. In comparison, 30
day all-cause mortality in the EU study and ENGAGE were 2.5% and 0.9%
respectively. At 1 year, there were no incidences of Type I/III endoleak, migration, or
conversion in either the US Pivotal or the EU study. Similarly, there was a 1% incidence
of Type I/III endoleak, no incidence of migration, and a 0.8% incidence of conversion
at 1 year in ENGAGE.
Conclusion: Early and midterm outcomes with the Endurant stent graft system in the
treatment of AAA are consistent across global studies with high clinical success and
low complication rates.
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Background: The multicenter, nonrandomized CABANA Study evaluated
periprocedural outcomes in high surgical risk patients with carotid artery stenosis
treated with the Carotid WALLSTENT plus FilterWire EZ Embolic Protection System
(Boston Scientific Corporation, Natick, MA).
Methods: The study enrolled 32.7% symptomatic and 67.3% asymptomatic patients
at high risk for carotid endarterectomy (CEA) due to prespecified anatomical criteria
and/or medical comorbidities. Study centers were grouped into 1 of 3 tiers based on
having high, medium, or low previous carotid artery stenting (CAS) experience while
individual operators were grouped by their CAS credential-based study training
requirements. Follow-up at 30 days included clinical evaluation and independent
neurologic and NIH stroke scale assessments. The primary endpoint was the 30-day
composite of major adverse events (MAE), including stroke, death, and myocardial
infarction (MI).
Results: Of the 1,097 enrolled patients, technical success was achieved in 1,010
(97.1%); the stroke rate (3.3% [34/1,025]) was a major contributing factor in the overall
rate of MAEs (4.6% [47/1,025]). Most strokes were ipsilateral (88.2%) and ischemic
(85.3%). The overall mortality was 1.3% (13/1,025); the MI rate was 0.5% (5/1,025).
There was no statistically significant association between MAE rates among the 3
center experience tiers (p=0.61) nor among the 3 operator training categories (p=0.26).
However, there was a weak trend towards lower MAE rates at centers with greater
experience and with operators with more CAS training.
Conclusion: Results demonstrate that CAS with Carotid WALLSTENT and FilterWire
EZ is a safe alternative to CEA in high surgical risk patients in routine clinical practice.
The study yielded a low composite rate of 30-day MAEs and low individual rates of
periprocedural stroke, death, and MI. These rates were consistent across centers with
varying levels of CAS experience and operators with varying levels of training on CAS
and the Carotid WALLSTENT/FilterWire EZ System.
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Background: Carotid artery stenting (CAS) has become a viable alternative to carotid
endarterectomy, especially in patients considered high risk for surgery due to medical
co-morbidities and anatomically challenging lesions. SAPPHIRE Worldwide is the
largest study to date to evaluate long-term outcomes of CAS in patients at high-risk
for surgery.
Methods: SAPPHIRE Worldwide is a multicenter, prospective, observational study
of CAS performed at multiple centers by physicians with varied experience and
utilizing a formal training program. The primary endpoint of major adverse events
(MAE) included death, myocardial infarction (MI) and all stroke at 30 days, and
ipsilateral stroke was assessed from 31 to 360 days.
Results: To date, over 10,000 patients have been enrolled at 325 participating centers
and completed 30-day follow-up. More than 7,600 patients have completed 1-year
follow-up evaluation. Thirty percent of patients enrolled were symptomatic, and 46%
were over the age of 75 years. At 30-day follow up, the rate of MAE was 4.5% (death
1.3%, MI 0.6%, all stroke 3.3%). Between 30 days and 1 year, 21 additional patients
suffered an ipsilateral stroke for a 1-year MAE rate of 6.1%. MAE was significantly
lower in patients with asymptomatic vs. symptomatic stenosis (5.1% vs. 8.6%,
p<0.0001), and in patients with anatomic high risk factors compared with physiologic
factors (4.2% vs.6.9%, p<0.0001). Age < 75 years was also associated with a lower
risk of adverse events than seen with older patients (4.5% vs. 8.1%, p<0.0001).
Conclusion: Long-term outcomes with this large cohort of patients undergoing CAS,
shows favorable results. The risk of ipsilateral stroke after the periprocedural period
was very low at 0.3%.
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Background: Little is available on the neointimal characteristics of the lesions with
late stent thrombosis (ST) after bare-metal stenting.
Methods: We evaluated 53 consecutive nonostial stent failure lesions in 53 patients
(8 ST and 45 restenoses) by optical coherence tomography.
Results: At the index procedure, 29 patients (55%) were treated for acute coronary
syndromes. The median duration of implant was 58.8 months (interquartile range, 8.8
to 117.7 months). Three ST patients (6%) presented with ST-segment elevation
myocardial infarction (STEMI), 1 (2%) with non-STEMI, and 4 (8%) with unstable
angina. Stent malapposition was detected in 12 lesions (23%). The risk of ST (n = 8)
versus restenosis (n = 45) was increased for the patients with low LVEF (mean ± SEM,
47.2 ± 3.2% versus 55.6 ± 1.6%, p = 0.04), high LDL/HDL cholesterol ratio (2.7 ± 0.2
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